# Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

> **NCT02023021** · PHASE2 · COMPLETED · sponsor: **Xian-Jun Yu** · enrollment: 80 (estimated)

## Conditions studied

- Stage IA Pancreatic Adenocarcinoma
- Stage IB Pancreatic Adenocarcinoma
- Stage IIA Pancreatic Adenocarcinoma
- Stage IIB Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT02023021
- **Lead sponsor:** Xian-Jun Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-06
- **Final completion:** 2019-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02023021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02023021, "Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02023021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*